Analysts expect Eli Lilly to report $12.1 billion in sales and $1.45 in adjusted earnings per share for the quarter. Eli ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Total European sales in this segment grew by 21.9%, underscoring the company’s expanding ambition in the region. The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 ...

One of the approvals is for Ebglyss, a treatment for atopic dermatitis that could displace the current market leader, ...

10/25, 根据周五在秋季临床皮肤病学 (FCD) 会议上公布的最新 IIIb 期数据，礼来公司（Lilly）$礼来(LLY)$最近获批的 IL-13 抑制剂 Ebglyss (lebrikizumab-lbkz) 在中度至重度特应性皮炎患者中表现出显著的皮肤清除和瘙痒缓解改善，这些患者之前已停用赛诺菲和再生元的 Dupixent (dupilumab)。 ADapt 研究的结果可能将 Ebgl ...

Probably the biggest objection to buying Lilly stock is its valuation. The big pharmaceutical company's shares trade at nearly 37.5 times forward earnings. Does this high multiple disqualify Lilly as ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Leerink Partners maintained its Outperform rating on Eli Lilly shares, indicating confidence in the company's performance. Eli Lilly's EBGLYSS, a drug for moderate-to-severe atopic dermatitis, has ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.